GTA-182

N/A

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameGTA-182
Drug Alias NameGTA182GTA-182
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein arginine methyltransferase 5 inhibitors
TargetsProtein arginine methyltransferase 5
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic Ductal +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Apeiron Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Apeiron Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic Ductal +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A